← Leaderboards
Peadar G Noone
University Of North Carolina Chapel Hill
$2,611,655
Attributed
$2,611,655
Total exposure
5
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$2,611,655 · 5
By mechanism
M01$2,236,004 · 4
K23$375,651 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Michael R Knowles$33,731,453
- David B Peden$24,843,616
- Christy K Scott$28,429,130
- Eugene P Orringer$33,565,484
- Brian J Boehlecke$676,049
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchCystic FibrosisHuman Genetic Material TagHuman Therapy EvaluationClinical Trial Phase IRespiratory EpitheliumMolecular PathologyChloride ChannelsFamily GeneticsGene MutationDrug Screening /EvaluationLung DisorderAdult Human (21+)Respiratory Disorder ChemotherapyRespiratory DisorderPlasmidsCholesterolGene TherapyGenetic MappingCilium /Flagellum MotilityLiposomesPhosphatidylcholinesDosage
Grant awards (25)
SAFETY AND BIOLOGICAL EFFICACY OF LIPID-DNA COMPLEX GR2134878$190,747
M01 · FY2002 · RR
GENETIC MUTATIONS IN PATIENTS W/ PRIMARY CILIARY DYSKINESIA &FAMILY$190,747
M01 · FY2002 · RR
PATHOGENESIS OF CF AND PCD LUNG DISEASE$125,217
K23 · FY2002 · HL
SAFETY AND BIOLOGICAL EFFICACY OF LIPID-DNA COMPLEX GR2134878$294,555
M01 · FY2001 · RR
GENETIC MUTATIONS IN PATIENTS W/ PRIMARY CILIARY DYSKINESIA &FAMILY$294,555
M01 · FY2001 · RR
GENETIC MUTATIONS IN PATIENTS W/ PRIMARY CILIARY DYSKINESIA &FAMILY$190,747
M01 · FY2001 · RR
SAFETY AND BIOLOGICAL EFFICACY OF LIPID-DNA COMPLEX GR2134878$190,747
M01 · FY2001 · RR
PATHOGENESIS OF CF AND PCD LUNG DISEASE$125,217
K23 · FY2001 · HL
SAFETY AND BIOLOGICAL EFFICACY OF LIPID-DNA COMPLEX GR2134878$294,555
M01 · FY2000 · RR
SAFETY AND BIOLOGICAL EFFICACY OF LIPID-DNA COMPLEX GR2134878$294,555
M01 · FY2000 · RR
SAFETY AND BIOLOGICAL EFFICACY OF LIPID-DNA COMPLEX GR2134878$294,555
M01 · FY2000 · RR
PATHOGENESIS OF CF AND PCD LUNG DISEASE$125,217
K23 · FY2000 · HL
SAFETY AND BIOLOGICAL EFFICACY OF LIPID-DNA COMPLEX GR2134878$241
M01 · FY2000 · RR
INHALED DOSES OF IB-367 IN ADULT CYSTIC FIBROSIS PATIENTS$0
M01 · FY2000 · RR
INHALED DOSES OF IB-367 IN ADULT CYSTIC FIBROSIS PATIENTS$0
M01 · FY2000 · RR
INHALED DOSES OF IB-367 IN ADULT CYSTIC FIBROSIS PATIENTS$0
M01 · FY2000 · RR
INHALED DOSES OF IB-367 IN ADULT CYSTIC FIBROSIS PATIENTS$0
M01 · FY2000 · RR
INS365 IN ADULT AND PEDIATRIC CYSTIC FIBROSIS PATIENTS$0
M01 · FY2000 · RR
INS365 IN ADULT AND PEDIATRIC CYSTIC FIBROSIS PATIENTS$0
M01 · FY2000 · RR
INS365 IN ADULT AND PEDIATRIC CYSTIC FIBROSIS PATIENTS$0
M01 · FY2000 · RR
GENETIC MUTATIONS IN PATIENTS W/ PRIMARY CILIARY DYSKINESIA &FAMILY$0
M01 · FY2000 · RR
GENETIC MUTATIONS IN PATIENTS W/ PRIMARY CILIARY DYSKINESIA &FAMILY$0
M01 · FY2000 · RR
GENETIC MUTATIONS IN PATIENTS W/ PRIMARY CILIARY DYSKINESIA &FAMILY$0
M01 · FY2000 · RR
GENETIC MUTATIONS IN PATIENTS W/ PRIMARY CILIARY DYSKINESIA &FAMILY$0
M01 · FY2000 · RR
INS365 IN ADULT AND PEDIATRIC CYSTIC FIBROSIS PATIENTS$0
M01 · FY2000 · RR